BAY 38-7271 was originally developed by Bayer AG before being licensed to KeyNeurotek Pharmaceuticals.
Warning: Last items in stock!
BAY 38-7271 was originally developed by Bayer AG before being licensed to KeyNeurotek Pharmaceuticals. This cannabinoid-receptor agonist is still being investigated but Phase II trials showed that it was found to improve the survival rate, cerebral perfusion, and neurological outcome of patients following Traumatic Brain Injury and ischaemic episodes. This drug therefore offers promising advances in the management of TBI and well as cerebral ischaemia. BAY 38-7271 has not been approved for human consumption but can be purchased legally all over the world and is supplied as as white powder.